Abstract
Background Mental health problems (MHP) in COVID-19 patients and survivors were anticipated already during early stages of this pandemic. We aimed to synthesize the prevalence of anxiety, depression, post-traumatic and general distress of major virus epidemics since 2002.
Methods In this systematic review and meta-analysis, we searched PubMed, PsycINFO, and Embase from 2002 until April 14, 2021 for peer-reviewed studies reporting prevalence of MHP in adults with laboratory-confirmed or suspected SARS-CoV-1, H1N1, MERS-CoV, H7N9, Ebolavirus, or SARS-CoV-2 infection. We included studies that assessed MHP with well-validated and frequently used scales. A three-level random-effects meta-analysis for dependent sizes was conducted to account for multiple outcome reporting. We pooled MHP jointly and separately for mild or moderate-to-severe severity by acute (one month), ongoing (one to three month), and post-illness phase (longer than three months). A meta-regression was conducted to test for moderating effects. PROSPERO registration: CRD42020194535.
Findings We identified 59 studies providing a total of 187 effect sizes. Range for sample size (n=14-n=1002), females (22-79%), and mean age (32-72 years). MHP prevalence was higher for mild (35·5-46·3%) compared to moderate-to-severe MPH (17·3-22·3). MHP, in general, decreased from acute to post-illness from 46·3% to 38·8% and for mild and moderate-to-severe from 22·3% to 18·8%, respectively. We found no evidence of moderating effects except for non-random sampling and H1N1 showing higher proportions.
Interpretation MHP decreased over time but were still on a substantial level at post-illness. This highlights a need for rapid access to mental health care and rehabilitation planning in affected individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approval required (systematic review).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Relevant data is provided in the manuscript.